The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents



      Angiotensin-converting enzyme inhibitors (ACEi), angiotensin II receptor blockers (ARBs), and HMG-CoA reductase inhibitors (“statins”) have been hypothesized to affect COVID-19 severity. However, up to now, no studies investigating this association have been conducted in the most vulnerable and affected population groups (ie, older adults residing in nursing homes). The objective of this study was to explore the association of ACEi/ARB and/or statins with clinical manifestations in COVID-19–infected older adults residing in nursing homes.


      We undertook a retrospective multicenter cohort study to analyze the association between ACEi/ARB and/or statin use with clinical outcome of COVID-19. The outcomes were (1) serious COVID-19 defined as long-stay hospital admission or death within 14 days of disease onset, and (2) asymptomatic (ie, no disease symptoms in the whole study period while still being diagnosed by polymerase chain reaction).

      Setting and participants

      A total of 154 COVID-19–positive subjects were identified, residing in 1 of 2 Belgian nursing homes that experienced similar COVID-19 outbreaks.


      Logistic regression models were applied with age, sex, functional status, diabetes, and hypertension as covariates.


      We found a statistically significant association between statin intake and the absence of symptoms during COVID-19 (odds ratio [OR] 2.91; confidence interval [CI] 1.27–6.71), which remained statistically significant after adjusting for covariates (OR 2.65; CI 1.13–6.68). Although the effects of statin intake on serious clinical outcome were in the same beneficial direction, these were not statistically significant (OR 0.75; CI 0.24–1.87). There was also no statistically significant association between ACEi/ARB and asymptomatic status (OR 2.72; CI 0.59–25.1) or serious clinical outcome (OR 0.48; CI 0.10–1.97).

      Conclusions and Implications

      Our data indicate that statin intake in older, frail adults could be associated with a considerable beneficial effect on COVID-19 clinical symptoms. The role of statins and renin-angiotensin system drugs needs to be further explored in larger observational studies as well as randomized clinical trials.


      To read this article in full you will need to make a payment


      Subscribe to Journal of the American Medical Directors Association
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kuba K.
        • Imai Y.
        • Rao S.A.
        • et al.
        A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury.
        Nat Med. 2005; 11: 875-879
        • Imai Y.
        • Kuba K.
        • Rao S.
        • et al.
        Angiotensin-converting enzyme 2 protects from severe acute lung failure.
        Nature. 2005; 436: 112-116
        • Wosten-van Asperen R.M.
        • Bos A.P.
        • Bem R.A.
        • et al.
        Imbalance between pulmonary angiotensin-converting enzyme and angiotensin-converting enzyme 2 activity in acute respiratory distress syndrome.
        Pediatr Crit Care Med. 2013; 14: E438-E441
        • Woesten-van Asperen R.M.
        • Lutter R.
        • Specht P.A.
        • et al.
        Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1–7) or an angiotensin II receptor antagonist.
        J Pathol. 2011; 225: 618-627
        • Jacobson J.R.
        • Barnard J.W.
        • Grigoryev D.N.
        • Ma S.F.
        • Tuder R.M.
        • Garcia J.G.
        Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury.
        Am J Physiol Lung Cell Mol Physiol. 2005; 288: L1026-L1032
        • Fedson D.S.
        Treating the host response to emerging virus diseases: Lessons learned from sepsis, pneumonia, influenza and Ebola.
        Ann Transl Med. 2016; 4: 421
        • McGonagle D.
        • Sharif K.
        • O'Regan A.
        • Bridgewood C.
        The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease.
        Autoimmun Rev. 2020; 19: 102537
        • McGonagle D.
        • O'Donnell J.
        • Sharif K.
        • et al.
        Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia.
        Lancet Rheum. 2020; ([Epub ahead of print])
        • Tang N.
        • Li D.
        • Wang X.
        • Sun Z.
        Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.
        J Thromb Haemostas. 2020; 18: 844-847
        • Yin S.
        • Huang M.
        • Li D.
        • Tang N.
        Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2.
        J Thromb Thrombolysis. 2020 Apr 3; ([Epub ahead of print])
        • van de Veerdonk F.
        • Netea M.G.
        • van Deuren M.
        • et al.
        Kinins and cytokines in COVID-19: A comprehensive pathophysiological approach, Preprints.
        2020 Apr 3 ([Epub ahead of print])
        • Schol-Gelok S.
        • Morelli F.
        • Arends L.R.
        • et al.
        A revised systematic review and meta-analysis on the effect of statins on D-dimer levels.
        Eur J Clin Invest. 2019; 49: e13130
        • Aktas S.
        • Ucak S.
        • Kurt F.
        • et al.
        Evaluation of protein C and protein S levels in patients with diabetes mellitus receiving therapy with statins and ACE inhibitors or angiotensin II receptor blockers.
        Diabetes Res Clin Pract. 2018; 135: 88-92
        • Teuwen L.-A.
        • Geldhof V.
        • Pasut A.
        • Carmeliet P.
        COVID-19: the vasculature unleashed.
        Nat Rev Immunol. 2020; 20: 389-391
        • Fedson D.S.
        • Opal S.M.
        • Rordam O.M.
        Hiding in plain sight: An approach to treating patients with severe COVID-19 infection.
        Mbio. 2020; 11: e00398
        • Reiner Z.
        • Hatamipour M.
        • Banach M.
        • et al.
        Statins and the COVID-19 main protease: In silico evidence on direct interaction.
        Arch Med Sci. 2020; 16: 490-496
        • Mortensen E.
        • Anzueto A.
        Prior use of both a statin and ARB is associated with lower mortality for patients hospitalized with pneumonia.
        Eur Respir J. 2016; 48: OA3329
        • Mortensen E.M.
        • Nakashima B.
        • Cornell J.
        • et al.
        Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes.
        Clin Infect Dis. 2012; 55: 1466-1473
        • Meng J.
        • Xiao G.
        • Zhang J.
        • et al.
        Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension.
        Emerg Microbes Infect. 2020; 9: 757-760
        • Bean D.
        • Kraljevic Z.
        • Searle T.
        • et al.
        Treatment with ACE-inhibitors is associated with less severe SARS-Covid-19 infection in a multi-site UK acute Hospital Trust.
        • Guang Y.
        • Zihu T.
        • Ling Z.
        • et al.
        Angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors usage is associated with improved inflammatory status and clinical outcomes in COVID-19 patients with hypertension, medRxiv.
        • Yingxia L.
        • Fengming H.
        • Jun X.
        • et al.
        Anti-hypertensive angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients, medRxiv.
        • Zhang P.
        • Zhu L.
        • Cai J.
        • et al.
        Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19.
        Circ Res. 2020; 126: 1671-1681
      1. COVID-19 – Epidemiologisch bulletin van 29 april 2020.
        (Available at:)
      2. 7,000 of US coronavirus deaths happened in association with nursing homes. That's almost 20% of all US deaths.
        (Available at:)
        • Lovato A.
        • de Filippis C.
        Clinical presentation of COVID-19: A systematic review focusing on upper airway symptoms.
        Ear Nose Throat J. 2020 Apr 13; ([Epub ahead of print])
        • Zhang Q.Y.
        Firth logistic regression for rare variant association tests.
        Front Genet. 2014; 5: 187
        • Firth D.
        Bias reduction of maximum-likelihood-estimates.
        Biometrika. 1993; 80: 27-38
        • McMichael T.M.
        • Currie D.W.
        • Clark S.
        • et al.
        Epidemiology of Covid-19 in a long-term care facility in King County, Washington.
        N Engl J Med. 2020; 382: 2005-2011
        • Onder G.
        • Rezza G.
        • Brusaferro S.
        Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy.
        JAMA. 2020 Mar 23; ([Epub ahead of print])
        • O'Dowd A.
        Covid-19: Deaths in care home deaths in England and Wales rise sharply.
        BMJ. 2020; 369: m1727
        • Abdulhak A.A.B.
        • Kashour T.
        • Noman A.
        • et al.
        Angiotensin converting enzyme inhibitors and angiotensin receptor blockers and outcome of COVID-19: A systematic review and meta-analysis.
        Perit Dial Int. 2009; 29: 554-561
        • Paranjpe I.
        • Fuster V.
        • Lala A.
        • et al.
        Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19.
        J Am Coll Cardiol. 2020; 76: 122-124
        • Cox C.E.
        Anticoagulants may aid COVID-19 patients, NYC data suggest.
        (Available at:)
        • Grein J.
        • Ohmagari N.
        • Shin D.
        • et al.
        Compassionate use of remdesivir for patients with severe Covid-19.
        N Engl J Med. 2020; 382: 2327-2336
        • Cao B.
        • Wang Y.
        • Wen D.
        • et al.
        A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19.
        N Engl J Med. 2020; 382: 1787-1799
        • Cortegiani A.
        • Ingoglia G.
        • Ippolito M.
        • et al.
        A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
        J Crit Care. 2020; 57: 279-283
        • Casadevall A.
        • Pirofski L.-A.
        The convalescent sera option for containing COVID-19.
        J Clin Invest. 2020; 130: 1545-1548